Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glucocorticoids | 7 | 2014 | 352 | 1.780 |
Why?
|
| Genome-Wide Association Study | 9 | 2023 | 1620 | 0.980 |
Why?
|
| Lymphocytes | 2 | 2013 | 464 | 0.760 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 241 | 0.670 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2014 | 120 | 0.660 |
Why?
|
| Phenotype | 7 | 2023 | 2377 | 0.640 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2023 | 2270 | 0.570 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 1135 | 0.560 |
Why?
|
| Pharmacogenomic Variants | 1 | 2015 | 41 | 0.520 |
Why?
|
| Mifepristone | 1 | 2014 | 33 | 0.500 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 124 | 0.500 |
Why?
|
| Dexamethasone | 3 | 2014 | 326 | 0.490 |
Why?
|
| Transcriptome | 4 | 2013 | 580 | 0.490 |
Why?
|
| Albumins | 1 | 2014 | 133 | 0.480 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2014 | 22 | 0.480 |
Why?
|
| Interleukin-6 | 2 | 2014 | 256 | 0.480 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 1920 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 199 | 0.450 |
Why?
|
| Genetic Markers | 1 | 2014 | 476 | 0.440 |
Why?
|
| Paclitaxel | 1 | 2014 | 460 | 0.440 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1578 | 0.430 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 166 | 0.420 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 819 | 0.390 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 103 | 0.390 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2015 | 549 | 0.390 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 196 | 0.350 |
Why?
|
| Blood Proteins | 2 | 2020 | 144 | 0.340 |
Why?
|
| Quantitative Trait Loci | 5 | 2018 | 576 | 0.340 |
Why?
|
| Crohn Disease | 2 | 2015 | 730 | 0.330 |
Why?
|
| Colitis, Ulcerative | 2 | 2015 | 711 | 0.330 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1195 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 2356 | 0.300 |
Why?
|
| Asthma | 2 | 2018 | 955 | 0.290 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 724 | 0.290 |
Why?
|
| Chromosome Mapping | 4 | 2019 | 1074 | 0.280 |
Why?
|
| Calcitriol | 2 | 2016 | 174 | 0.240 |
Why?
|
| Meta-Analysis as Topic | 2 | 2023 | 87 | 0.230 |
Why?
|
| Disease | 1 | 2023 | 90 | 0.210 |
Why?
|
| Humans | 19 | 2023 | 86601 | 0.200 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1384 | 0.200 |
Why?
|
| Gene Frequency | 1 | 2023 | 677 | 0.190 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2887 | 0.190 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 43 | 0.190 |
Why?
|
| Proteome | 1 | 2020 | 124 | 0.180 |
Why?
|
| Albuminuria | 1 | 2019 | 153 | 0.160 |
Why?
|
| Drug Discovery | 1 | 2018 | 103 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2016 | 1351 | 0.150 |
Why?
|
| Adaptive Immunity | 2 | 2014 | 164 | 0.140 |
Why?
|
| Endophenotypes | 1 | 2015 | 17 | 0.130 |
Why?
|
| Heredity | 1 | 2015 | 19 | 0.130 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 22 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 78 | 0.120 |
Why?
|
| CD3 Complex | 1 | 2014 | 135 | 0.120 |
Why?
|
| CD28 Antigens | 1 | 2014 | 88 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2015 | 260 | 0.120 |
Why?
|
| Immunity, Innate | 2 | 2014 | 409 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2012 | 1565 | 0.120 |
Why?
|
| Genetic Linkage | 1 | 2015 | 623 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2014 | 256 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 286 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2818 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 689 | 0.110 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2011 | 8 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 41 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 246 | 0.100 |
Why?
|
| Italy | 1 | 2011 | 106 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 154 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 827 | 0.100 |
Why?
|
| Nigeria | 1 | 2011 | 152 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2013 | 429 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 280 | 0.100 |
Why?
|
| United Kingdom | 2 | 2023 | 164 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 339 | 0.090 |
Why?
|
| Genotype | 1 | 2015 | 1850 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 534 | 0.090 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 164 | 0.090 |
Why?
|
| Alleles | 1 | 2013 | 1127 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 434 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2013 | 444 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2014 | 395 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1197 | 0.090 |
Why?
|
| Middle Aged | 6 | 2023 | 25017 | 0.080 |
Why?
|
| Young Adult | 3 | 2015 | 5974 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1718 | 0.080 |
Why?
|
| Genetic Loci | 2 | 2019 | 250 | 0.070 |
Why?
|
| Female | 5 | 2018 | 44507 | 0.070 |
Why?
|
| Genomics | 1 | 2011 | 720 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2436 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2015 | 8475 | 0.060 |
Why?
|
| Adult | 4 | 2018 | 25640 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1720 | 0.060 |
Why?
|
| Estonia | 1 | 2023 | 1 | 0.060 |
Why?
|
| Finland | 1 | 2023 | 29 | 0.060 |
Why?
|
| Risk Factors | 3 | 2019 | 5416 | 0.060 |
Why?
|
| Male | 5 | 2018 | 40956 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2018 | 2767 | 0.050 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 10 | 0.040 |
Why?
|
| Lipase | 1 | 2018 | 22 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 24 | 0.040 |
Why?
|
| Creatinine | 1 | 2019 | 338 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 119 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 26581 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 294 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 266 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 148 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 3241 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 129 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 812 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 599 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 273 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 88 | 0.030 |
Why?
|
| Electron Transport | 1 | 2013 | 71 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 357 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 678 | 0.030 |
Why?
|
| Vitamins | 1 | 2013 | 81 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 303 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 352 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 1204 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2705 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2018 | 1196 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 806 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 1185 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 296 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1456 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2468 | 0.020 |
Why?
|
| Aged | 2 | 2015 | 18402 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6501 | 0.020 |
Why?
|
| United States | 1 | 2015 | 6665 | 0.010 |
Why?
|